Buscar resultados de ensayos clínicos
Ewing Sarcoma - 29 Studies Found
Estado | Estudiar |
Terminated |
Nombre del estudio: Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma Condición:
Fecha: 2012-05-31 Intervenciones: Drug: Mithramycin Phase I Portion: Mithramycin will be administered in escalating doses to children and |
Completed |
Nombre del estudio: Genetic Biomarkers in Saliva Samples From Patients With Ewing Sarcoma Condición: Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET) Fecha: 2013-06-10 Intervenciones:
|
Completed |
Nombre del estudio: Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors Condición:
|
Completed |
Nombre del estudio: Study of Tumor Samples From Patients With Ewing Sarcoma Condición: Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Fecha: 2009-05-09 Intervenciones: Other: laboratory biomarker analysis Correlative studies |
Completed |
Nombre del estudio: Osteosarcoma and Ewing Sarcoma Treatment Response Assessment With Functional MRI Imaging in Children and Young Adults Condición:
Fecha: 2013-01-23 Intervenciones: Other: MRI MRI exam will be performed in all patients incl |
RECRUITING |
Nombre del estudio: Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma Condición: Ewing Sarcoma Fecha: 2024-05-18 Intervenciones: Participants will receive cabozantinib in combination with high-dose ifosfamide for 5 cycles.If still on study therapy the participants will con |
RECRUITING |
Nombre del estudio: Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma Condición: Refractory Ewing Sarcoma Fecha: 2024-05-18 Intervenciones: Administered as intravenous (IV) infusion once every 3 weeks (Q3W) |
RECRUITING |
Nombre del estudio: Lurbinectedin in FET-Fused Tumors Condición: Ewing Sarcoma Fecha: 2024-05-18 Intervenciones: Lurbinectedin will be administered on a Day 1, Day 4 schedule every 21 days.Doses will be determined in the phase 1 portion of the trial. |
COMPLETED |
Nombre del estudio: Perioperative Use of Tranexamic (TXA) in Bone Tumor Surgery Will Change in Blood Loss and Transfusion Requirements. Condición: Ewing Sarcoma of Bone Fecha: 2024-05-18 Intervenciones: . TXA, a lysine analogue, reversibly binds to the plasminogen lysine receptors and thereby blocks plasminogen from binding to fibrin (tPA can only act |